echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Phase 3 clinical results of Bayer's "first-in-class" therapy released

    Phase 3 clinical results of Bayer's "first-in-class" therapy released

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Bayer announced that its "first-in-class" therapy Kerendia (finerenone), a phase 3 clinical trial FIGARO-DKD in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) The primary end point was reached


    Kerendia is a non-steroidal selective mineralocorticoid receptor antagonist (MRA)


    Unlike the previous phase 3 clinical trials, the main patients of FIGARO-DKD have milder symptoms of grade 1-2 CKD (eGFR ≥60 ml/min/1.


    ▲The primary endpoint data of the FIGARO-DKD clinical trial (picture source: reference [2])

    Reference materials:

    [1] Bayer Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 Diabetes.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.